- Home
- TYRA vs NLOP Comparison
TYRA vs NLOP Comparison
Compare TYRA & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NLOP
- Stock Information
- Founded
- TYRA 2018
- NLOP N/A
- Country
- TYRA United States
- NLOP United States
- Employees
- TYRA N/A
- NLOP N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NLOP
- Sector
- TYRA Health Care
- NLOP
- Exchange
- TYRA Nasdaq
- NLOP Nasdaq
- Market Cap
- TYRA 580.2M
- NLOP 498.8M
- IPO Year
- TYRA 2021
- NLOP N/A
- Fundamental
- Price
- TYRA $10.37
- NLOP $32.87
- Analyst Decision
- TYRA Strong Buy
- NLOP Strong Buy
- Analyst Count
- TYRA 7
- NLOP 1
- Target Price
- TYRA $30.86
- NLOP $46.00
- AVG Volume (30 Days)
- TYRA 231.1K
- NLOP 49.5K
- Earning Date
- TYRA 08-11-2025
- NLOP 01-01-0001
- Dividend Yield
- TYRA N/A
- NLOP 1.04%
- EPS Growth
- TYRA N/A
- NLOP N/A
- EPS
- TYRA N/A
- NLOP N/A
- Revenue
- TYRA N/A
- NLOP $127,453,000.00
- Revenue This Year
- TYRA N/A
- NLOP N/A
- Revenue Next Year
- TYRA N/A
- NLOP N/A
- P/E Ratio
- TYRA N/A
- NLOP N/A
- Revenue Growth
- TYRA N/A
- NLOP N/A
- 52 Week Low
- TYRA $6.42
- NLOP $26.10
- 52 Week High
- TYRA $29.60
- NLOP $34.53
- Technical
- Relative Strength Index (RSI)
- TYRA 48.30
- NLOP 48.45
- Support Level
- TYRA $10.71
- NLOP $33.04
- Resistance Level
- TYRA $11.66
- NLOP $34.08
- Average True Range (ATR)
- TYRA 0.63
- NLOP 0.60
- MACD
- TYRA -0.01
- NLOP -0.10
- Stochastic Oscillator
- TYRA 18.25
- NLOP 13.54
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.